Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1986-6-30
pubmed:abstractText
Gold sodium thiomalate (GST) is known to modify the disease process in patients with active rheumatoid arthritis (RA). To help understand the mechanism of action of GST, several immunological parameters were prospectively evaluated in 10 patients with active RA following the introduction of gold therapy. Before therapy, absolute numbers of peripheral blood T suppressor/cytotoxic lymphocytes were significantly depressed (P less than 0.01) and a raised T helper/T suppressor cell ratio was found. After 1 g of GST, an absolute reduction in total lymphocyte numbers including HLA/DR positive mononuclear cells, was evident (P less than 0.01). This lymphopenic effect was not selective for a single population since the proportions of T cells, T cell subsets and B cells remained unchanged. Lymphocyte function was also examined. Raised in vitro production of IgG (P less than 0.01) and IgA (P less than 0.05) was found before therapy. After GST, in vitro immunoglobulin synthesis was reduced and this was significant with respect to the IgM (P less than 0.001) and IgA (P less than 0.01) isotypes. Similarly, a parallel reduction in serum immunoglobulin levels developed. GST therapy was also associated with a reduced proliferative response to phytohaemagglutinin, concanavalin A and pokeweed mitogen in the initial phase of gold administration. The significant finding in this study suggest that the in vivo immunosuppressive effect of GST is explained not only by impaired mononuclear cell function but also by a significant reduction in T and B lymphocyte numbers.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/3086003-100121, http://linkedlifedata.com/resource/pubmed/commentcorrection/3086003-117813, http://linkedlifedata.com/resource/pubmed/commentcorrection/3086003-3923951, http://linkedlifedata.com/resource/pubmed/commentcorrection/3086003-406862, http://linkedlifedata.com/resource/pubmed/commentcorrection/3086003-4213688, http://linkedlifedata.com/resource/pubmed/commentcorrection/3086003-426886, http://linkedlifedata.com/resource/pubmed/commentcorrection/3086003-448083, http://linkedlifedata.com/resource/pubmed/commentcorrection/3086003-5006477, http://linkedlifedata.com/resource/pubmed/commentcorrection/3086003-5135623, http://linkedlifedata.com/resource/pubmed/commentcorrection/3086003-6224467, http://linkedlifedata.com/resource/pubmed/commentcorrection/3086003-6228352, http://linkedlifedata.com/resource/pubmed/commentcorrection/3086003-6433938, http://linkedlifedata.com/resource/pubmed/commentcorrection/3086003-6603939, http://linkedlifedata.com/resource/pubmed/commentcorrection/3086003-6887161, http://linkedlifedata.com/resource/pubmed/commentcorrection/3086003-7160107, http://linkedlifedata.com/resource/pubmed/commentcorrection/3086003-811742, http://linkedlifedata.com/resource/pubmed/commentcorrection/3086003-838859
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
0009-9104
pubmed:author
pubmed:issnType
Print
pubmed:volume
63
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
614-20
pubmed:dateRevised
2009-11-18
pubmed:meshHeading
pubmed:year
1986
pubmed:articleTitle
The immunological consequences of gold therapy: a prospective study in patients with rheumatoid arthritis.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't